Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jonathan A. Fletcher, M.D.

Title
Institution
Department
Address
Phone
Fax
Other Positions
Title
Institution
Department

Mentoring
Available: 10/17/18, Expires: 10/16/22

Our lab translates advances in cancer biology into effective targeted therapies for adult and pediatric sarcomas. Current priorities include: 1) rational combination therapies; 2) new strategies for targeting oncogenic tyrosine kinases and the dysregulated cell cycle; 3) maximizing therapeutic response by targeting mechanisms of genetic/biologic progression in sarcomas. The student can participate in designing clinical trials of drugs validated in the laboratory studies. We lead several international research consortia in these fields, leading to rich collaborations and interactions.

Characterizing Dystrophin as a Prognostic Biomarker in Surgically-resected GIST
Summer, 04/01/13 - 08/19/13

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P50CA127003 (BASS, ADAM JOEL) Apr 1, 2007 - Jun 30, 2018
    NIH/NCI
    SPORE: DF/HCC SPORE in GASTROINTESTINAL CANCER
    Role: Co-Principal Investigator
  2. R01CA072791 (FLETCHER, JONATHAN A) Sep 19, 1997 - Aug 31, 2000
    NIH/NCI
    TRANSLOCATION OF 8-13 IN STEM-CELL LEUKEMIA/LYMPHOMA
    Role: Principal Investigator
  3. R01CA068376 (FLETCHER, JONATHAN A) Apr 5, 1996 - Mar 31, 1999
    NIH/NCI
    TUMOR SUPPRESSOR LOCI IN MESOTHELIOMA
    Role: Principal Investigator
  4. P01CA068484 (SALLAN, STEPHEN E) Sep 30, 1995 - Apr 30, 2013
    NIH/NCI
    Therapeutic Index of Acute Lymphoblastic Leukemia
    Role: Co-Principal Investigator
  5. P20NS031110 (BLACK, PETER M) Sep 30, 1992 - Jun 30, 1996
    NIH/NINDS
    CHARACTERIZING AND INHIBITING ASTROCYTOMA GROWTH
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Yen CC, Chen LT, Li CF, Chen SC, Chua WY, Lin YC, Yen CH, Chen YC, Yang MH, Chao Y, Fletcher JA. Identification of phenothiazine as an ETV1-targeting agent in gastrointestinal stromal tumors using the Connectivity Map. Int J Oncol. 2019 Jun 21. PMID: 31268158.
    Citations:    
  2. Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA. Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 May 23. PMID: 31123346.
    Citations:    
  3. Yan C, Brunson DC, Tang Q, Do D, Iftimia NA, Moore JC, Hayes MN, Welker AM, Garcia EG, Dubash TD, Hong X, Drapkin BJ, Myers DT, Phat S, Volorio A, Marvin DL, Ligorio M, Dershowitz L, McCarthy KM, Karabacak MN, Fletcher JA, Sgroi DC, Iafrate JA, Maheswaran S, Dyson NJ, Haber DA, Rawls JF, Langenau DM. Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. Cell. 2019 Jun 13; 177(7):1903-1914.e14. PMID: 31031007.
    Citations:    
  4. Heinrich MC, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S. Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs). Clin Sarcoma Res. 2019; 9:3. PMID: 30867899.
    Citations:    
  5. Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 Mar; 120(6):612-620. PMID: 30792533.
    Citations:    
  6. Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018 12; 8(12):1548-1565. PMID: 30322867.
    Citations:    Fields:    
  7. Klug LR, Bannon AE, Javidi-Sharifi N, Town A, Fleming WH, VanSlyke JK, Musil LS, Fletcher JA, Tyner JW, Heinrich MC. LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma. Oncogene. 2019 02; 38(8):1200-1210. PMID: 30242244.
    Citations:    Fields:    
  8. Tsai HJ, Jiaang WT, Shih NY, Fletcher JA, Lin MJ, Yang MY, Chen CT, Hsu TJ, Wu CC, Lin HY, Chen LT. BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor. Cancer Sci. 2018 Nov; 109(11):3591-3601. PMID: 30142229.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  9. Cao M, Carrasco RD, Dubuc AM, Dal Cin P, Fletcher JA, Xiao S. ZMYM2-FGFR1 fusion as secondary change in acute myeloid leukemia. Leuk Lymphoma. 2019 Feb; 60(2):556-558. PMID: 30160587.
    Citations:    Fields:    
  10. Hemming ML, Lawlor MA, Zeid R, Lesluyes T, Fletcher JA, Raut CP, Sicinska ET, Chibon F, Armstrong SA, Demetri GD, Bradner JE. Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A. 2018 06 19; 115(25):E5746-E5755. PMID: 29866822.
    Citations:    Fields:    Translation:HumansCells
  11. Schaefer IM, Fletcher JA, Nielsen GP, Shih AR, Ferrone ML, Hornick JL, Qian X. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy. Cancer Cytopathol. 2018 08; 126(8):552-566. PMID: 29757500.
    Citations:    Fields:    
  12. Mariño-Enriquez A, Lauria A, Przybyl J, Ng TL, Kowalewska M, Debiec-Rychter M, Ganesan R, Sumathi V, George S, McCluggage WG, Nucci MR, Lee CH, Fletcher JA. BCOR Internal Tandem Duplication in High-grade Uterine Sarcomas. Am J Surg Pathol. 2018 03; 42(3):335-341. PMID: 29200103.
    Citations: 2     Fields:    
  13. Schaefer IM, Mariño-Enríquez A, Fletcher JA. What is New in Gastrointestinal Stromal Tumor? Adv Anat Pathol. 2017 Sep; 24(5):259-267. PMID: 28632504.
    Citations: 1     Fields:    Translation:HumansCells
  14. Chen W, Kuang Y, Qiu HB, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y, Meng F, Fletcher JA, Ou WB. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Cancer Res. 2017 09 15; 77(18):5107-5117. PMID: 28760855.
    Citations:    Fields:    Translation:HumansAnimalsCells
  15. Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol. 2017 Jul 01; 3(7):944-952. PMID: 28196207.
    Citations: 11     Fields:    Translation: